



NOTICE

Notice is hereby given that the extraordinary general meeting of shareholders (the **Extraordinary General Meeting**) of TME Pharma N.V. (the **Company**) is convened at 13.30 hours (CEST) on 30 September 2024 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands. The language of the meeting shall be English.

You do not need to be present to cast your vote at the Extraordinary General Meeting on 30 September 2024. Instead, you can give your voting instructions by proxy. Further details on participation, voting or representation by proxy are given in the Attendance Notice for this Extraordinary General Meeting available on the Company's corporate website: <https://www.tmepharma.com> (the **Company's Website**).

Shareholders who decide not to attend the Extraordinary General Meeting on 30 September 2024 in Amsterdam, the Netherlands, and who wish to submit questions regarding items on the agenda of the Extraordinary General Meeting, may submit their questions by email to shareholders@tmepharma.com up to 17.00 hours (CEST) on 27 September 2024. The email submitting such question(s) must include name, surname, number of shares held by the shareholder on 02 September 2024 (the Registration Date as defined below) and the agenda item to which the question relates.

AGENDA

The Extraordinary General Meeting is convened to discuss and decide on the following:

Agenda

- 1. Opening**
- 2. Appointment of Dr. Alexandra Glucksmann as member of the supervisory board (voting)**
- 3. Close of meeting**

Berlin, Federal Republic of Germany, 27 August 2024

The board of directors



EXPLANATORY NOTES

Agenda item 2 – Appointment of Dr. Alexandra Glucksmann as member of the supervisory board (voting)

The supervisory board is of the view that the current development and performance of the Company and its strategy support enlarging the supervisory board to five members. Considering the profile and composition of the supervisory board, the supervisory board has made the following binding nomination: to appoint Dr. Alexandra Glucksmann as additional member of the supervisory board.

Dr. Alexandra Glucksmann (age 65 on 30 September 2024, Brookline, Massachusetts, USA) is a seasoned US biopharma executive and experienced scientist with over 30 years of managerial experience in biotech. She is currently President and CEO of Sensorium Therapeutics, a private CNS focused biotech company, and serves on the board of Directors of Regenxbio, a US NASDAQ listed pre-commercial biotech focused on gene therapy.

Previously, she was President and CEO at Cedilla Therapeutics and an Entrepreneur-in-Residence at Venture Capital firm Third Rock Ventures where she focused on company formation. During her tenure at Cedilla, she successfully led the company from its launch through to Series B, securing significant funding of \$138 million.

Earlier in her career, Dr. Glucksmann was a founding employee and the Chief Operating Officer at Editas Medicine, where she helped raise a total of \$280 million from launch to IPO. She was also a founding employee and Senior Vice President of Research and Business Operations at Cerulean Pharma.

She began her career at Millennium Pharmaceuticals as a research scientist and held roles of increasing responsibility, culminating in the role of Vice President of platform technology groups, prior to transitioning into a senior position in strategic program management and operations.

Dr. Glucksmann earned her Ph.D. with honors in Molecular Genetics and Cell Biology from the University of Chicago in 1989 and completed her postdoctoral fellowship at the Massachusetts Institute of Technology in 1993.

Dr. Glucksmann currently does not hold any shares in the capital of the Company.

The first term of office of Dr. Alexandra Glucksmann as supervisory board member will be as from the Extraordinary General Meeting up to and including the annual general meeting of shareholders to be held in 2026.

ATTENDANCE INFORMATION

Extraordinary General Meeting documentation

The Extraordinary General Meeting documentation:

- agenda and the explanatory notes to the agenda; and
- instructions and documents for participation and voting at the Extraordinary General Meeting,

are available on the Company's Website. These documents are also available at the Company's offices at Max-Dohrn-Strasse 8-10, 10589 Berlin, Federal Republic of Germany, for shareholders and persons entitled to attend the meeting who, upon request, will receive a copy free of charge.

Participation and voting

Under Dutch law and the Company's articles of association, persons entitled to attend and to vote at the Extraordinary General Meeting are shareholders of the Company (which for the purposes of this notice includes holders of a Dutch law right of usufruct and/or a right of pledge (if applicable and if such right includes meeting rights)) who (i) were registered as shareholder in one of administration records of the intermediaries that are (indirectly) participants in Euroclear France on 02 September 2024 (the **Registration Date**) after all debit and credit entries have been handled as per the Registration Date and (ii) have notified the Company by 17.00 hours (CEST) on 23 September 2024 of their attendance in writing or electronically (contact details at the end of this announcement). You do not need to be present to cast your vote at the Extraordinary General Meeting on 30 September 2024. Instead, you can give your voting instructions by proxy.

Representation by proxy

Subject to compliance with the provisions above, shareholders who cannot attend and vote at the Extraordinary General Meeting in person, may also be represented at the Extraordinary General Meeting by proxy. In order to be eligible to give proxy and voting instructions, the relevant shareholder must ensure that (i) he or she is registered as a shareholder in the manner as described above and (ii) the duly completed and signed proxy including, as appropriate, voting instructions, are received by the Company by 17.00 hours (CEST) on 23 September 2024 in writing or electronically (contact details at the end of this announcement). Shareholders who cannot attend and vote in person, are urged to give proxy and voting instructions to Bert Spijkervet, deputy civil law notary with Freshfields Bruckhaus Deringer LLP, by completing the power of attorney form available on the Company's Website under "Attendance notice and PoA".



Attendance card

Shareholders who have notified the Company of their attendance (either in person or by proxy), will receive an attendance card issued in their name. This will serve as admission certificate and prior to the start of the Extraordinary General Meeting, the shareholder (or his or her proxy) will need to hand over the attendance card, and as applicable the written power of attorney, at the registration desk before being allowed to enter the Extraordinary General Meeting.

Identification

Persons entitled to attend the Extraordinary General Meeting may be requested to identify themselves at the registration desk prior to admission to the Extraordinary General Meeting and are therefore requested to bring a valid identity document.

Address details of the Company:

TME Pharma N.V.
Attn: Mrs. K.C. Ophoff, general counsel
Max-Dohrn-Strasse 8-10
10589 Berlin
Federal Republic of Germany
e-mail: shareholders@tmepharma.com